semaglutide competitors FirstpostNews: Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent Pay once, save all year—with

Long-term effects of externally administered MOTS-c remain unknown

Dec 8, 2023- A federal justice in Louisiana quashed Novo Nordisks request to dismiss one of the first lawsuits filed against Novo Nordisk concerning complications of Ozempic

This is where Inno Shred GLP-1 steps inby boosting your bodys natural GLP-1 production, it fights against hunger, reduces food cravings, and supports fat burning

VK0214, oral TR agonist for X-linked adrenoleukodystrophy (X-ALD) Recent Highlights: In June 2026, Viking announced that its working toward maintenance-dosing data for subcutaneous VK2735 and preparing to start Phase 3 trials of the oral tablet in Q4 2026, with the goal of becoming the first company to offer a dual GLP-1/GIP agonist in both oral and injectable form

Z., Baisch, D

DPP-4 inhibitors (DPP-4i) enhance plasma levels of GLP-1 and several other GI hormones including GIP by inhibiting their degradation